Anti-inflammatory properties of ebselen in a model of sephadex-induced lung inflammation

European Respiratory Journal

Volumn 15, Issue 3, 2000, Pages 579-581

  Belvisi, M G ^a   Haddad, E B ^a   Battram, C ^a   Birrell, M ^a   Foster, M ^a   Webber, S ^a  

^a Aventis Pharma Ltd   (United Kingdom)

Author keywords

Airway inflammation; Lung oedema; Sephadex; Tumour necrosis factor

Indexed keywords

EBSELEN; ENDOTHELIN 1; SEPHADEX; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHIOLITIS; CYTOKINE PRODUCTION; DRUG ACTIVITY; LUNG EDEMA; LUNG LAVAGE; LUNG WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOLES; DEXTRANS; MALE; ORGANOSELENIUM COMPOUNDS; PULMONARY EDEMA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034016461     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.15.25.x     Document Type: Article

References (14)

1. Cotgreave IA, Johansson U, Westergren G, Moldeus PW, Brattsand R. The anti-inflammatory activity of Ebselen but not thiols in experimental alveolitis and bronchiolitis. Agents Actions 1988; 24: 313-319.
2. Källstrom L, Brattsand R, Lövgren U, Svensjö E, Roempke K. A rat model for testing anti-inflammatory action in lung and the effect of glucocorticosteroids (CGS) in this model. Agents Actions 1985; 17: 355-357.
3. Sics H. Ebselen, a selenoorganic compound as glutathione peroxide mimic. Free Radical Biol Med 1993; 14: 313-323.
4. Parnham M. The pharmaceutical potential of seleno-organic compounds. Exp Opin Invest Drugs 1996; 5: 861-870.
5. Wendel A, Tiegs G. A novel biologically active seleno-organic compound VI. Protection by ebselen (PZ51) against glactosamine/endotoxin-induced hepatitis in mice. Biochem Pharmacol 1986; 35: 2115-2118.
6. Ying S, Robinson DS, Varney V, et al. TNF-α mRNA expression in allergic inflammation. Clin Exp Allergy 1991; 21: 745-750.
7. Gosset P, Tsicopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor α and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. J Allergy Clin Immunol 1991; 88: 561-571.
8. Redington AE, Springall DR, Ghatei A, et al. Endothelin bronchoalveolar lavage fluid and its relation to airflow obstruction in asthma. Am J Respir Crit Care Med 1995; 151: 1034-1039.
9. Springall DR, Howarth PH, Counihan H, Djukanovic S, Holgate ST, Polak JM. Endothelin immunoreactivity of airway epithelium in asthmatic patients. Lancet 1991; 337: 697-70.
10. Renzetti LM, Paciorek PM, Tannu SA, et al. Pharmacological evidence for tumour necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 1996; 278: 847-853.
11. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax 1998; 53: 137-147.
12. Williams CMM, Smith L, Flanagan BF, Clegg LS, Coleman JW. Tumour necrosis factor-α expression and cell recruitment in Sephadex particle-induced lung inflammation: effects of dexamethasone and cyclosporin A. Br J Pharmacol 1997; 122: 1127-1134.
13. Golden CL, Kohler HS, Nick HS, Visner GA. Effects of vasoactive and inflammatory mediators on endothelin-1 expression in pulmonary endothelial cells. Am J Respir Cell Mol Biol 1995; 22: 503-512.
14. Finsnes F, Skønsberg OH, Tønnessen T, Næss O, Lyberg T, Christensen G. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 1997; 155: 1404-1412.